focus -WSS

focus

author：hotspot 2025-09-28 23:44:52 - browse：57684

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： The high personal cost of affirmative action for Black doctors

focus

entertainment

WSS

Vertex non

‘Oppenheimer’ and the risks of AI in health care

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Thermo Fisher plant for manufacturing gene therapies to expand

What to expect as Trump is arraigned on his Jan 6. indictment

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

leisure time

focus

hotspot

In Memoriam: Notable people who died in 2023

Why are Kaiser Permanente staff considering a strike?

Psychedelics group wrestles with new pharma identity

Wildfire pollution widens asthma inequities on Long Island

Alkermes shareholders re

Pence says 'crackpot lawyers' told Trump what he wanted to hear

What does generative AI mean for health care? We asked experts

What the US credit downgrade means for the economy, your finances

State Dept. review finds Biden bears some blame for Afghanistan failures

CDC's new outbreak response network to include Northeastern

focus

CDC advisers recommend seasonal use of Pfizer RSV shot

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Amazon expands telehealth clinic nationwide

Ukraine and a new approach to mental health in war

EQRx, failed developer of low

Infectious disease expert Jeanne Marrazzo assumes Fauci role

explore

focus

entertainment

leisure time